 |
Infinity Pharmaceuticals to Present at UBS Conference
Sep 12, 2011
|
6.8 KB |
|
| |
CAMBRIDGE, Mass., Sept. 12, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at UBS Global Life Sciences Conference on Monday, September 19, 2011 at 2:00 p.m. ET in New York City.
A live webcast of Infinity's presentation will be accessible on the "investors/media" section of the company's website, www.in...
|
|
Infinity Pharmaceuticals to Present at Two Upcoming Conferences
Aug 30, 2011
|
6.8 KB |
|
| |
CAMBRIDGE, Mass., Aug. 30, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Stifel Nicolaus Healthcare Conference on Wednesday, September 7, 2011 at 10:20 a.m. ET in Boston.
In addition, Infinity will also be presenting at the Rodman & Renshaw Annual Global Investment Conference on Monday, Septembe...
|
|
Infinity Reports Second Quarter 2011 Financial Results
Aug 9, 2011
|
23.6 KB |
|
| |
CAMBRIDGE, Mass., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today highlighted its recent clinical and business progress and announced its second quarter 2011 financial results. During the quarter, the company continued to advance its pipeline of novel drug candidates while maintaining a strong financial profile.
...
|
|
Infinity Announces the Date of Its Second Quarter 2011 Financial Results Conference Call and Webcast
Aug 2, 2011
|
7.1 KB |
|
| |
CAMBRIDGE, Mass., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, August 9, 2011 at 4:30 p.m. ET. During the call, management will provide an update on Infinity's business and discuss the company's second quarter 2011 financial results.
A live webcast of the conference call c...
|
|
Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway
Jun 22, 2011
|
21.2 KB |
|
| |
CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small molecule that inhibits Smoothened, a key component of the Hedgehog pathway. As part of this expansion, Infinity plans to initiate an exploratory Phase...
|
|
Infinity Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer at ASCO Meeting
Jun 6, 2011
|
13.3 KB |
|
| |
CHICAGO, June 6, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from a Phase 1b trial of retaspimycin hydrochloride (HCl) (also known as IPI-504), its novel heat shock protein 90 (Hsp90) inhibitor, in combination with docetaxel (also known as Taxotere®) in patients with non-small cell ...
|
|
Infinity Reports Results From Phase 1b Clinical Trial of IPI-926, an Oral Smoothened Antagonist, in Pancreatic Cancer at ASCO Meeting
Jun 4, 2011
|
14.2 KB |
|
| |
CHICAGO, June 4, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of IPI-926 in combination with the chemotherapy gemcitabine (also known as Gemzar®) in patients with previously untreated, metastatic pancreatic cancer. The...
|
|
Infinity to Highlight Clinical Progress and Review Abstracts to be Presented at ASCO Annual Meeting
Jun 1, 2011
|
17.0 KB |
|
| |
— Company to Host Webcast and Conference Call Today at 8:30 a.m. ET with Dr. Gregory Riely, Principal Investigator for Ongoing Phase 2 Trial of Retaspimycin HCl, a Novel Hsp90 Inhibitor —
— IPI-926, an Oral Smoothened Antagonist, Granted Orphan Drug Designation in Europe for Treatment of Chondrosarcoma —
CAMBRI...
|
|
Infinity Pharmaceuticals to Present at Jefferies Conference
May 31, 2011
|
6.7 KB |
|
| |
CAMBRIDGE, Mass., May 31, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at Jefferies Global Healthcare Conference on Wednesday, June 8, 2011 at 9:30 a.m. ET in New York City.
A live webcast of Infinity's presentation will be accessible on the "investors/media" section of the company's website, www.infi...
|
|
Infinity Initiates Randomized Phase 2 Trial of IPI-504, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer
May 19, 2011
|
13.6 KB |
|
| |
CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of a Phase 2 clinical trial of retaspimycin hydrochloride (HCl), also known as IPI-504, the company's novel heat shock protein (Hsp90) inhibitor, in combination with docetaxel (also known as Taxotere®) in patients with...
|
|
Infinity Announces Clinical Data to be Presented at ASCO
May 19, 2011
|
13.6 KB |
|
| |
CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that clinical data for IPI-926, its novel Smoothened antagonist, and retaspimycin hydrochloride (IPI-504), its novel Hsp90 inhibitor, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). Both i...
|
|
Infinity Reports First Quarter 2011 Financial Results
May 10, 2011
|
21.5 KB |
|
| |
— Reaffirms 2011 Financial Guidance and Provides Additional Details —
— Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer by Year End —
CAMBRIDGE, Mass., May 10, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today highlighted its recent clinical a...
|
|
Infinity Announces the Date of Its First Quarter 2011 Financial Results Conference Call and Webcast
May 3, 2011
|
7.2 KB |
|
| |
CAMBRIDGE, Mass., May 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, May 10, 2011 at 4:30 p.m. ET. During the call, management will provide an update on Infinity's business and discuss first quarter 2011 financial results.
A live webcast of the conference call can be accessed in ...
|
|
Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development
Apr 11, 2011
|
10.3 KB |
|
| |
CAMBRIDGE, Mass., April 11, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the appointment of Joshua D. Hamermesh as vice president, business and corporate development, with responsibility for the company's corporate strategy and business development initiatives. Mr. Hamermesh joins Infinity with over a dozen ...
|
|
Infinity Pharmaceuticals to Present at BioCentury Future Leaders Conference
Apr 7, 2011
|
6.9 KB |
|
| |
CAMBRIDGE, Mass., April 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at BioCentury's 18th Annual Future Leaders in the Biotech Industry Conference on Friday, April 15, 2011 at 11:00 a.m. ET in New York City.
A live webcast of Infinity's presentation will be accessible on the "investors/media" secti...
|
|
Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma
Apr 3, 2011
|
13.7 KB |
|
| |
CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical model of chondrosarcoma, a life-threatening cancer of the cartilage. The data demonstrated that IPI-926 inhibited tumor growth and led to tumor calcificat...
|
|
Infinity to Present New Preclinical Data on IPI-926, a Novel Smoothened Antagonist Targeting the Hedgehog Pathway, at Upcoming AACR Meeting
Mar 23, 2011
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., March 23, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that the company will present new preclinical data supporting ongoing development of IPI-926 in chondrosarcoma during the American Association for Cancer Research (AACR) 102nd Annual Meeting being held in Orlando, Florida from April 2 t...
|
|
Infinity Provides Company Update and Reports Fourth Quarter and Full-Year 2010 Financial Results
Mar 15, 2011
|
21.2 KB |
|
| |
IPI-926 Advancing in Two Phase 2 Trials, Underscoring Pipeline MomentumCash Runway Into 2014 Enables Advancement of Product Candidates to
Key Inflection PointsCompany Changes Accounting Treatment for the $50 Million Line of Credit Available from Purdue
CAMBRIDGE, Mass., March 15, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nas...
|
|
Infinity Announces the Date of Its Fourth Quarter 2010 Financial Results Conference Call and Webcast
Mar 8, 2011
|
7.0 KB |
|
| |
CAMBRIDGE, Mass., March 8, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, March 15, 2011 at 4:30 p.m. ET. During the call, management will provide an update on Infinity's business and discuss fourth quarter 2010 financial results.
A live webcast of the conference call can be accesse...
|
|
Infinity Initiates Phase 2 Trial of IPI-926 in Patients With Chondrosarcoma
Mar 3, 2011
|
14.2 KB |
|
| |
— Company Granted U.S. Orphan Drug Designation for IPI-926 for the Treatment of Chondrosarcoma — — Rationale for Developing IPI-926 in Chondrosarcoma to be Highlighted During a Hedgehog Pathway Symposium at AACR —
CAMBRIDGE, Mass., March 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of a...
|
|
|
